The International ITP Registry
- Conditions
- Thrombocytopenia
- Registration Number
- NCT01970189
- Lead Sponsor
- South Eastern Sydney Local Health District
- Brief Summary
Primary immune thrombocytopenia (ITP) is an uncommon disease characterised by a low platelet count, which may cause the patient to have a higher risk or increased duration of bleeding. Individual hospitals only encounter a small number of ITP patients each year which makes it difficult to study this disease. By creating this disease registry, we will be able to build a more complete picture of ITP, including treatment practices, through collecting information about the condition from patients across several hospitals in several countries. Research of this kind will help future patients by providing doctors with information about ITP, and about how patients have been treated.
- Detailed Description
This is an observational disease registry database for recently-diagnosed adult patients with primary ITP that aims to understand the natural history of this rare disease and disease management. Participating investigators will prospectively enter real-world patient data on their enrolled patients with a minimum of 2 years follow up.
Data from this registry will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and adverse outcomes (resulting from treatment or disease) on ITP patients on an annual basis. The information will be generated at the national or combined-country level. Furthermore, each institution will have an access to its data and may choose to generate descriptive statistics for its specific institution on a more frequent, ad-hoc basis. New research questions or questions addressing a subset of registry patients to take advantage of combined registry data will require a separate protocol and review by independent committees
The focus of this protocol is on adults with primary ITP, however, in future there may be interest to expand the population to explore secondary ITP patients as well. Hence, this registry is built to allow for some optional preliminary information related to secondary ITP to be captured.
Multi-site participation of this registry project will be rolled out in stages, and will be offered to centres with appropriate expertise. Pilot countries included Australia, Korea, Taiwan, Singapore, Malaysia, Japan, Thailand and Turkey and sites will be selected based on their potential research (interest, resources, and expected patient volume). Additional sites may be added in the future from countries in Asia Pacific, Middle East and Latin America. Japan has an independent national ITP registry run by the government, however voluntary participation of interested Japanese investigators in this database will be welcomed, therefore allowing comparison of data between Japanese and non-Japanese patients.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
- Recently-diagnosed (i.e. < 6 months) primary ITP adults patients (≥ 18 years) characterized by platelet counts less than 100x109/L as defined by the International Working Group1.
- Able to provide written consent for data to be included in the registry
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease progression of ITP up to 24 months This will include response assessment to each treatment modality, incidence and characteristics of bleeding events, bone marrow results (if available), development of refractory ITP and effects of any medical intervention (whether beneficial or detrimental) in the overall severity of the disease, according to definitions described by the ITP International Working Group.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (44)
Ramathibodi Hospital
🇹🇭Bangkok, Thailand
Siriraj Hospital
🇹🇭Bangkok, Thailand
Ankara Oncology Training and Research Hospital
🇹🇷Ankara, Turkey
Ankara University
🇹🇷Ankara, Turkey
Pamukkale University Medical Faculty
🇹🇷PAmukkale, Turkey
Samsung Medical Centre
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
ASAN Medical Centre
🇰🇷Seoul, Korea, Republic of
Seoul St Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital
🇰🇷Seoul, Korea, Republic of
Subang Jaya Medical Centre
🇲🇾Kuala Lumpur, Malaysia
Mackay Memorial Hospital
🇨🇳Taiwan, Taiwan
National Cheng Kung University Hospital
🇨🇳Taiwan, Taiwan
Taipei Veteran's General Hospital
🇨🇳Taipei, Taiwan
China Medical University Hospital
🇨🇳TAiwan, Taiwan
Concord Hospital
🇦🇺Sydney, New South Wales, Australia
St George Hospital
🇦🇺Sydney, New South Wales, Australia
Liverpool Hospital
🇦🇺Sydney, New South Wales, Australia
Prince of Wales Hospital
🇦🇺Sydney, New South Wales, Australia
Flinders Medical Centre
🇦🇺Adelaide, South Australia, Australia
Canberra Hospital
🇦🇺Canberra, Australian Capital Territory, Australia
Calvary Mater Newcastle
🇦🇺Sydney, New South Wales, Australia
Royal Adelaide Hospital
🇦🇺Adelaide, South Australia, Australia
The Alfred
🇦🇺Melbourne, Victoria, Australia
St Vincent's Hospital
🇦🇺Melbourne, Victoria, Australia
Foscal
🇨🇴Busaramanga, Colombia
Hemato-Oncologos
🇨🇴Colombia, Colombia
Hospital Pablo Tobón Uribe
🇨🇴Colombia, Colombia
Mubarak Alkabeer Hospital
🇰🇼Kuwait City, Kuwait
Penang Hospital
🇲🇾Penang, Malaysia
Ampang Hospital
🇲🇾Kuala Lumpur, Malaysia
National University Hospital
🇸🇬Singapore, Singapore
Singapore General Hospital
🇸🇬Singapore, Singapore
Taichung Veteran's General Hospital
🇨🇳Taiwean, Taiwan
Chiang Mai University
🇹🇭Chiang Mai, Thailand
Pramongkutlao College of MEdicine
🇹🇭Thailand, Thailand
Chulalongkorn University
🇹🇭Thailand, Thailand
Ankara Numune Training and Research Hosptial
🇹🇷Ankara, Turkey
Dokuz Eylul University Medical Faculty
🇹🇷Turkey, Turkey
Erciyes University Medical Faculty
🇹🇷Turkey, Turkey
Gaziantep University Medical Faculty
🇹🇷Turkey, Turkey
Hospital Britanico
🇺🇾Uruguay, Uruguay
CASMU
🇺🇾Uruguay, Uruguay
Hospital Militar
🇺🇾Uruguay, Uruguay